A Randomized Clinical Trial of Trimetazidine, a Partial Free Fatty Acid Oxidation Inhibitor, in Patients With Heart Failure

Journal of the American College of Cardiology

Volumn 48, Issue 5, 2006, Pages 992-998

  Fragasso, Gabriele ^a   Palloshi, Altin ^a   Puccetti, Patrizia ^a   Silipigni, Carmen ^a   Rossodivita, Alessandra ^a   Pala, Mariagrazia ^a   Calori, Giliola ^a   Alfieri, Ottavio ^a   Margonato, Alberto ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC ACID DERIVATIVE; TRIMETAZIDINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXERCISE TOLERANCE; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HUMAN; MALE; MEDICAL SOCIETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TWO DIMENSIONAL ECHOCARDIOGRAPHY; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; CARDIAC OUTPUT, LOW; ECHOCARDIOGRAPHY; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HEART; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; TREATMENT OUTCOME; TRIMETAZIDINE; VASODILATOR AGENTS; VENTRICULAR FUNCTION, LEFT;

EID: 33747887613     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.03.060     Document Type: Article

References (48)

1. Passeron J. Efficacy of trimetazidine in stable effort angina. Double-blind study against placebo. Presse Med 15 (1986) 1775-1777
2. Michaelides A.P., Vyssoulis G.P., Bonoris P.E., Psaros T.K., Papadopoulos P.D., and Toutouzas P.K. Beneficial effects of trimetazidine in men with stable angina under beta-blocker treatment. Curr Ther Res 46 (1989) 565-566
3. Levy S., and Group of South of France Investigators. Combination therapy of trimetazidine with diltiazem in patients with coronary artery disease. Am J Cardiol 76 (1995) 12B-16B
4. Dalla-Volta S., Maraglino G., Della-Valentina P., Viena P., and Desideri A. Comparison of trimetazidine with nifedipine in effort angina. a double blind, cross-over study. Cardiovasc Drug Ther 4 (1990) 853-860
5. Detry J.M., Sellier P., Pennaforte S., Cokkinos D., Dargie H., and Mathes P. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Br J Clin Pharmacol 37 (1994) 279-388
6. Chierchia S.L., and Fragasso G. Protective effects of trimetazidine on ischaemic myocardial dysfunction. Eur Heart J (1999) 24-27 l Suppl O:O
7. 31P-NMR spectroscopy in the isolated rat heart. Arch Int Pharmacodyn Ther 286 (1987) 97-110
8. Fragasso G., De Cobelli F., Perseghin G., et al. Improved myocardial high-energy phosphate metabolism induced by partial fatty acid inhibition in patients with heart failure. J Am Coll Cardiol 43 (2004) 190A
9. i in the rat isolated ventricular myocyte. Br J Pharmacol 117 (1996) 831-838
10. 2* regulation by trimetazidine during cardiac cell acidosis. Cardiovasc Drugs Ther 1 (1988) 677-686
11. Maridonneau-Parini I., and Harpey C. Effects of trimetazidine on membrane damage induced by oxygen free radicals in human red cells. Br J Clin Pharmacol 20 (1985) 148-151
12. Kay L., Finelli C., Aussedat J., et al. Improvement of long-term preservation of the isolated arrested rat heart by trimetazidine. effects on the energy state and mitochondrial function. Am J Cardiol 76 (1995) 45B-49B
13. Fantini E., Demaison L., Sentex E., et al. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Mol Cell Cardiol 26 (1994) 949-958
14. Kantor P.F., Lucien A., Kozak R., et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 86 (2000) 580-588
15. Brottier L., Barat J.L., Combe C., Boussens B., Bonnet J., and Bricaud H. Therapeutic value of a cardioprotective agent in patients with severe ischemic cardiomyopathy. Eur Heart J 11 (1990) 207-212
16. Lu C., Dabrowski P., Fragasso G., and Chierchia S.L. Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease. a double-blind, placebo-controlled, crossover study. Am J Cardiol 82 (1998) 898-901
17. Belardinelli R., and Purcaro A. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy. Eur Heart J 22 (2001) 2164-2170
18. Fragasso G., Piatti P.M., Monti L., et al. Short and long term beneficial effects of partial free fatty acid inhibition in diabetic patients with ischemic dilated cardiomyopathy. Am Heart J 146 (2003) E1-E8
19. Vitale C., Wajngaten M., Sposato B., et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 25 (2004) 1814-1821
20. Di Napoli P., Taccardi A.A., and Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart 91 (2005) 161-165
21. Essop M.F., and Opie L.H. Metabolic therapy for heart failure. Eur Heart J 25 (2004) 1765-1768
22. Thrainsdottir I., von Bibra H., Malmberg K., and Ryden L. Effects of trimetazidine on left ventricular function in patients with type 2 diabetes and heart failure. J Cardiovasc Pharmacol 44 (2004) 101-108
23. O'Leary C.J., and Jones P.W. The left ventricular dysfunction questionnaire (LVD-36). reliability, validity, and responsiveness. Heart 83 (2000) 634-640
24. Oliver M.F. Glucose, insulin, potassium in acute myocardial infarction. Acta Cardiologica 28 Suppl 17 (1973) 257-266
25. Vik-Mo H., Riemersma R.A., Mjos O.D., et al. Effect of myocardial ischemia and antilipolytic agents on lipolysis and fatty acid metabolism in the in situ dog heart. Scand J Clin Lab Invest 39 (1979) 559-568
26. Lewis C.M., and Brink A.J. Beta adrenergic blockade. Hemodynamics and myocardial energy metabolism in patients with ischemic heart disease. Am J Cardiol 21 (1968) 846-859
27. Armstrong P.W., Chiong M.A., and Parker J.O. Effects of propranolol on the hemodynamic, coronary sinus blood flow and myocardial metabolic response to atrial pacing. Am J Cardiol 40 (1977) 83-89
28. Bagger J.P., Botker H.E., Thomassen A., and Nielsen T.T. Effects of ranolazine on ischemic threshold, coronary sinus blood flow, and myocardial metabolism in coronary artery disease. Cardiovasc Drugs Ther 11 (1997) 479-484
29. Lopaschuk G.D., Spafford M.A., Davies N.J., et al. Glucose and palmitate oxidation in isolated working rat hearts reperfused after a period of transient global ischaemia. Circ Res 66 (1990) 546-553
30. Lopaschuk G.D., and Saddik M. The relative contribution of glucose and fatty acids to ATP production in hearts reperfused following ischemia. Mol Cell Biochem 116 (1992) 111-116
31. Monti L.D., Setola E., Fragasso G., et al. Metabolic and endothelial effects of trimetazidine on forearm skeletal muscle in patients with type 2 diabetes and ischemic cardiomyopathy. Am J Physiol Endocrinol Metab 290 (2005) e54-e59
32. Pittman J.G., and Cohen P. The pathogenesis of cardiac cachexia. N Engl J Med 271 (1964) 403-409
33. Neely J.R., Rovetto M.J., and Oram J.F. Myocardial use of carbohydrate and lipids. Progr Cardiovasc Dis 15 (1972) 289-329
34. Lommi J., Kupari M., Koskinen P., et al. Blood ketone bodies in congestive heart failure. J Am Coll Cardiol 28 (1996) 665-672
35. Riley M., Bell N., Elborn J.S., Stanford C.F., Buchanan K.D., and Nicholls D.P. Metabolic response to graded exercise in chronic heart failure. Eur Heart J 14 (1993) 1484-1488
36. Paolisso G., De Riu S., Marrazzo G., Verza M., Varricchio M., and D'Onofrio F. Insulin resistance and hyperinsulinemia in patients with chronic heart failure. Metabolism 40 (1991) 972-977
37. Stacpoole P.W. The pharmacology of dichloroacetate. Metabolism 38 (1989) 1124-1144
38. Mc Veigh J.J., and Lopaschuck G.D. Dichloroacetate stimulation of glucose oxidation improves recovery of ischemic rat hearts. Am J Physiol 259 (1990) H1070-H1085
39. Nicholl T.A., Lopaschuck G.D., and McNeill G.H. Effects of free fatty acids and dichloroacetate on isolated working diabetic rat hearts. Am J Physiol 261 (1991) H1053-H1059
40. Bersin R.M., Wolfe C., Kwasman M., et al. Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate. J Am Coll Cardiol 23 (1994) 1617-1624
41. McAllister A., Allison S.P., and Randle P.J. Effects of dichloroacetate on the metabolism of glucose, pyruvate, acetate, 3-hydroxybutyrate and palmitate in rat diaphragm and heart muscle in vitro and on extraction of glucose, lactate, pyruvate and free fatty acids by dog heart in vivo. Biochem J 134 (1973) 1067-1081
42. Oliver M.F., and Opie L.H. Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias. Lancet 343 (1994) 155-158
43. deVillalobos D.H., and Taegtmeyer H. Metabolic support for the postischemic heart. Lancet 345 (1995) 1552-1555
44. Lopaschuck G.D., and Stanley W.C. Glucose metabolism in the ischemic heart. Circulation 95 (1997) 313-315
45. Katz A.M. Is the failing heart energy depleted?. Cardiol Clin 16 (1998) 633-644
46. Sentex E., Sergiel J.P., Lucien A., and Grynberg A. Trimetazidine increases phospholipid turnover in ventricular myocytes. Mol Cell Biochem 175 (1997) 153-162
47. Murray A.J., Anderson R.E., Watson G.C., Radda G.K., and Clarke K. Uncoupling proteins in human heart. Lancet 364 (2004) 1786-1788
48. Opie L.H. The metabolic vicious circle in heart failure. Lancet 364 (2004) 1733-1734